Delcath Systems Inc is an oncology company... Show more
Industry MedicalNursingServices
A.I.dvisor indicates that over the last year, DCTH has been loosely correlated with NVST. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if DCTH jumps, then NVST could also see price increases.
| Ticker / NAME | Correlation To DCTH | 1D Price Change % | ||
|---|---|---|---|---|
| DCTH | 100% | +3.33% | ||
| NVST - DCTH | 38% Loosely correlated | +0.94% | ||
| CERS - DCTH | 35% Loosely correlated | +2.41% | ||
| GKOS - DCTH | 34% Loosely correlated | +2.30% | ||
| ISRG - DCTH | 34% Loosely correlated | +2.38% | ||
| IRMD - DCTH | 34% Loosely correlated | +0.38% | ||
More | ||||
| Ticker / NAME | Correlation To DCTH | 1D Price Change % |
|---|---|---|
| DCTH | 100% | +3.33% |
| Health Services category (242 stocks) | 2% Poorly correlated | -1.33% |
| Medical/Nursing Services category (141 stocks) | 2% Poorly correlated | -1.32% |
The 10-day RSI Indicator for DCTH moved out of overbought territory on August 20, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 instances where the indicator moved out of the overbought zone. In 27 of the 32 cases the stock moved lower in the days that followed. This puts the odds of a move down at 84%.
The Moving Average Convergence Divergence Histogram (MACD) for DCTH turned negative on August 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 31 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DCTH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 60 cases where DCTH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on September 14, 2026. You may want to consider a long position or call options on DCTH as a result. In 77 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
Following a +4.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where DCTH advanced for three days, in 208 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. DCTH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 56 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.634) is normal, around the industry mean (10.773). DCTH's P/E Ratio (1618.000) is considerably higher than the industry average of (69.103). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.679). DCTH has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.018). P/S Ratio (6.743) is also within normal values, averaging (36.025).